Skip to main content
. 2017 Oct 10;8(55):94619–94634. doi: 10.18632/oncotarget.21816

Figure 6. LY2624587 antibody induced mobilization of WBCs and HSCs in human clinical trial patients with advanced cancer.

Figure 6

LY2624587 (CXCR4 mAb) induced changes in (A) total WBCs and (B) CD34+ HSCs at study baseline and cycles 1 to 3 of 900-mg once-weekly dosing. (C) LY2624587 (CXCR4 mAb) serum concentrations after 900-mg once-weekly dose. Values above or below data points indicate number of patients in standard error computation.